Literature DB >> 15947104

Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture.

Eleonore Fröhlich1, Fausto Machicao, Richard Wahl.   

Abstract

Differentiating drugs may be able to re-sensitize thyroid carcinomas to radioiodine therapy. Substituted thiazolidinediones (TZDs) belong to the group of oral anti-diabetic drugs that also possess anti-proliferative and pro-apoptotic effects and, potentially, differentiating effects on several cancer cell lines. Some of the effects are mediated via the peroxisome proliferator-activated receptor gamma (PPAR-gamma). We investigated the effect of troglitazone, rosiglitazone and pioglitazone on differentiation in normal porcine thyrocytes and in the follicular carcinoma cell lines FTC 133 and FTC 238. Differentiation was investigated by measuring 125I uptake and the expression of sodium-iodide symporter and thyroglobulin proteins. The TZDs were tested in the presence of retinol and retinoic acid. Additionally, proliferation was evaluated by [3H]thymidine uptake and cell number and apoptosis by annexin V-labeling. Controls included tocopherol and unsubstituted thiazolidinedione and co-incubation of the TZDs with the PPAR-gamma antagonist GW9662. PPAR-gamma and retinol X receptor (RXR)-alpha were investigated by immunocytochemistry, Western blot and RT-PCR. Cells derived from the metastasis showed greater responses than cells derived from the primary tumor. Troglitazone showed greater effects than the other TZDs. Troglitazone significantly increased 125I uptake and apoptosis and decreased [3H]thymidine uptake and cell number. The amount of the sodium iodide-symporter in the membrane fraction was significantly increased, while that of thyroglobulin was not influenced by the treatment. Inclusion of antagonist did not abolish these effects. No synergistic effect with any retinoid was detected. All transformed cells expressed PPAR-gamma and RXR-alpha but TZDs did not change their expression. Troglitazone appears to be suited for the re-differentiation treatment of dedifferentiated thyroid carcinoma because its action is twofold. On the one hand it increases differentiation and on the other hand it inhibits proliferation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15947104     DOI: 10.1677/erc.1.00973

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  18 in total

Review 1.  Novel approaches in anaplastic thyroid cancer therapy.

Authors:  Kun-Tai Hsu; Xiao-Min Yu; Anjon W Audhya; Juan C Jaume; Ricardo V Lloyd; Shigeki Miyamoto; Tomas A Prolla; Herbert Chen
Journal:  Oncologist       Date:  2014-09-26

2.  Heterozygous deletion of Seipin in islet beta cells of male mice has an impact on insulin synthesis and secretion through reduced PPARγ expression.

Authors:  Jianwei Xiong; Peng Sun; Ya Wang; Xu Hua; Wenyu Song; Yan Wang; Jie Wu; Wenfeng Yu; George Liu; Ling Chen
Journal:  Diabetologia       Date:  2019-11-27       Impact factor: 10.122

3.  Thyroid cancer: pathogenesis and targeted therapy.

Authors:  David A Liebner; Manisha H Shah
Journal:  Ther Adv Endocrinol Metab       Date:  2011-10       Impact factor: 3.565

Review 4.  Alternative medical treatment for radioiodine-refractory thyroid cancers.

Authors:  Jin Chul Paeng; Keon Wook Kang; Do Joon Park; So Won Oh; June-Key Chung
Journal:  Nucl Med Mol Imaging       Date:  2011-09-17

Review 5.  Novel treatments for anaplastic thyroid carcinoma.

Authors:  Silvia Martina Ferrari; Giusy Elia; Francesca Ragusa; Ilaria Ruffilli; Concettina La Motta; Sabrina Rosaria Paparo; Armando Patrizio; Roberto Vita; Salvatore Benvenga; Gabriele Materazzi; Poupak Fallahi; Alessandro Antonelli
Journal:  Gland Surg       Date:  2020-01

Review 6.  The paramount role of cytokines and chemokines in papillary thyroid cancer: a review and experimental results.

Authors:  Poupak Fallahi; Silvia Martina Ferrari; Simona Piaggi; Michaela Luconi; Giulia Cantini; Stefania Gelmini; Giusy Elia; Ilaria Ruffilli; Alessandro Antonelli
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

7.  Troglitazone-activated PPARγ inhibits LPS-induced lung alveolar type II epithelial cells injuries via TNF-α.

Authors:  Bo Xiao; Jing Xu; Guansong Wang; Peng Jiang; Fang Fang; Jian Huang; Jianchun Wang
Journal:  Mol Biol Rep       Date:  2010-12-14       Impact factor: 2.316

8.  Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines.

Authors:  Eleonore Fröhlich; Peter Brossart; Richard Wahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-24       Impact factor: 9.236

9.  Inhibitory effects of retinoic acid on invasiveness of human thyroid carcinoma cell lines in vitro.

Authors:  L Lan; D Cui; Y Luo; B Y Shi; L L Deng; G Y Zhang; H Wang
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

Review 10.  Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer.

Authors:  X Cai; R Wang; J Tan; Z Meng; N Li
Journal:  Clin Transl Oncol       Date:  2021-06-08       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.